SK264192A3 - Direct molecular cloning of modificated gen of eucaryotic cytoplasmic dna-virus - Google Patents
Direct molecular cloning of modificated gen of eucaryotic cytoplasmic dna-virus Download PDFInfo
- Publication number
- SK264192A3 SK264192A3 SK2641-92A SK264192A SK264192A3 SK 264192 A3 SK264192 A3 SK 264192A3 SK 264192 A SK264192 A SK 264192A SK 264192 A3 SK264192 A3 SK 264192A3
- Authority
- SK
- Slovakia
- Prior art keywords
- sequence
- gene
- virus
- plasmid
- dna
- Prior art date
Links
- 230000001086 cytosolic effect Effects 0.000 title claims abstract description 61
- 238000010369 molecular cloning Methods 0.000 title claims abstract description 36
- 241000700605 Viruses Species 0.000 claims abstract description 598
- 108020004414 DNA Proteins 0.000 claims abstract description 255
- 230000003612 virological effect Effects 0.000 claims abstract description 186
- 239000013598 vector Substances 0.000 claims abstract description 144
- 238000003776 cleavage reaction Methods 0.000 claims abstract description 138
- 238000000034 method Methods 0.000 claims abstract description 138
- 230000007017 scission Effects 0.000 claims abstract description 138
- 238000010367 cloning Methods 0.000 claims abstract description 126
- 102000053602 DNA Human genes 0.000 claims abstract description 94
- 208000015181 infectious disease Diseases 0.000 claims abstract description 53
- 238000004806 packaging method and process Methods 0.000 claims abstract description 46
- 210000002845 virion Anatomy 0.000 claims abstract description 41
- 230000002458 infectious effect Effects 0.000 claims abstract description 40
- 108091008146 restriction endonucleases Proteins 0.000 claims abstract description 36
- 108700026244 Open Reading Frames Proteins 0.000 claims abstract description 10
- 238000011144 upstream manufacturing Methods 0.000 claims abstract description 10
- 239000013612 plasmid Substances 0.000 claims description 359
- 108090000623 proteins and genes Proteins 0.000 claims description 340
- 210000004027 cell Anatomy 0.000 claims description 267
- 125000003729 nucleotide group Chemical group 0.000 claims description 229
- 239000002773 nucleotide Substances 0.000 claims description 228
- 241000700618 Vaccinia virus Species 0.000 claims description 204
- 239000012634 fragment Substances 0.000 claims description 201
- 150000007523 nucleic acids Chemical class 0.000 claims description 158
- 230000014509 gene expression Effects 0.000 claims description 125
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 117
- 108091034117 Oligonucleotide Proteins 0.000 claims description 114
- 108700005077 Viral Genes Proteins 0.000 claims description 97
- 238000003780 insertion Methods 0.000 claims description 92
- 230000037431 insertion Effects 0.000 claims description 92
- 101150106093 gpt gene Proteins 0.000 claims description 86
- 238000010276 construction Methods 0.000 claims description 84
- 239000000835 fiber Substances 0.000 claims description 73
- 239000003550 marker Substances 0.000 claims description 62
- 201000006082 Chickenpox Diseases 0.000 claims description 59
- 206010046980 Varicella Diseases 0.000 claims description 59
- 206010046865 Vaccinia virus infection Diseases 0.000 claims description 58
- 208000007089 vaccinia Diseases 0.000 claims description 58
- 108010042407 Endonucleases Proteins 0.000 claims description 57
- 108091081024 Start codon Proteins 0.000 claims description 56
- 241000700647 Variola virus Species 0.000 claims description 54
- 108020004705 Codon Proteins 0.000 claims description 43
- 229960005486 vaccine Drugs 0.000 claims description 41
- 102000004533 Endonucleases Human genes 0.000 claims description 39
- 108020005202 Viral DNA Proteins 0.000 claims description 39
- 230000029087 digestion Effects 0.000 claims description 39
- 239000000523 sample Substances 0.000 claims description 37
- 101150003725 TK gene Proteins 0.000 claims description 34
- 102000004169 proteins and genes Human genes 0.000 claims description 32
- 235000018102 proteins Nutrition 0.000 claims description 31
- 108010066124 Protein S Proteins 0.000 claims description 30
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 29
- 108010076282 Factor IX Proteins 0.000 claims description 29
- 230000001580 bacterial effect Effects 0.000 claims description 29
- 238000002474 experimental method Methods 0.000 claims description 28
- 238000012986 modification Methods 0.000 claims description 28
- 230000004048 modification Effects 0.000 claims description 28
- 229940096437 Protein S Drugs 0.000 claims description 27
- 102000029301 Protein S Human genes 0.000 claims description 27
- 229960004222 factor ix Drugs 0.000 claims description 27
- 241000588724 Escherichia coli Species 0.000 claims description 25
- 241000287828 Gallus gallus Species 0.000 claims description 24
- 238000002105 Southern blotting Methods 0.000 claims description 24
- 150000001413 amino acids Chemical group 0.000 claims description 24
- 235000001014 amino acid Nutrition 0.000 claims description 23
- 101150066555 lacZ gene Proteins 0.000 claims description 23
- 241000271566 Aves Species 0.000 claims description 21
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 21
- 238000004458 analytical method Methods 0.000 claims description 21
- 238000012217 deletion Methods 0.000 claims description 21
- 238000012360 testing method Methods 0.000 claims description 21
- 230000014616 translation Effects 0.000 claims description 21
- 238000005215 recombination Methods 0.000 claims description 20
- 230000006798 recombination Effects 0.000 claims description 20
- 108090000790 Enzymes Proteins 0.000 claims description 19
- 230000037430 deletion Effects 0.000 claims description 19
- 210000002950 fibroblast Anatomy 0.000 claims description 19
- 238000013519 translation Methods 0.000 claims description 19
- 102000004190 Enzymes Human genes 0.000 claims description 18
- 108010051456 Plasminogen Proteins 0.000 claims description 18
- 210000001161 mammalian embryo Anatomy 0.000 claims description 18
- 102000013566 Plasminogen Human genes 0.000 claims description 17
- 238000013459 approach Methods 0.000 claims description 17
- 238000013518 transcription Methods 0.000 claims description 17
- 230000035897 transcription Effects 0.000 claims description 17
- 108091026890 Coding region Proteins 0.000 claims description 16
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 16
- 238000004113 cell culture Methods 0.000 claims description 16
- 238000009396 hybridization Methods 0.000 claims description 16
- 230000010076 replication Effects 0.000 claims description 16
- 238000012546 transfer Methods 0.000 claims description 16
- 210000004962 mammalian cell Anatomy 0.000 claims description 15
- 241000700662 Fowlpox virus Species 0.000 claims description 14
- 108020004440 Thymidine kinase Proteins 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 14
- 101710163270 Nuclease Proteins 0.000 claims description 13
- 238000001727 in vivo Methods 0.000 claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
- 210000003501 vero cell Anatomy 0.000 claims description 13
- 230000009471 action Effects 0.000 claims description 12
- 230000000295 complement effect Effects 0.000 claims description 12
- 238000011534 incubation Methods 0.000 claims description 12
- 108010094028 Prothrombin Proteins 0.000 claims description 11
- 102100027378 Prothrombin Human genes 0.000 claims description 11
- 101150036274 kil gene Proteins 0.000 claims description 11
- 238000002703 mutagenesis Methods 0.000 claims description 11
- 231100000350 mutagenesis Toxicity 0.000 claims description 11
- 229940039716 prothrombin Drugs 0.000 claims description 11
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 10
- 210000005260 human cell Anatomy 0.000 claims description 10
- 239000002609 medium Substances 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- 239000000047 product Substances 0.000 claims description 10
- 238000012216 screening Methods 0.000 claims description 10
- 239000000499 gel Substances 0.000 claims description 9
- 230000012010 growth Effects 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- 238000000746 purification Methods 0.000 claims description 9
- 238000012163 sequencing technique Methods 0.000 claims description 9
- 101000605403 Homo sapiens Plasminogen Proteins 0.000 claims description 8
- 102000006601 Thymidine Kinase Human genes 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 8
- 239000011543 agarose gel Substances 0.000 claims description 8
- 238000003556 assay Methods 0.000 claims description 8
- 230000008901 benefit Effects 0.000 claims description 8
- 238000012856 packing Methods 0.000 claims description 8
- 229920001184 polypeptide Polymers 0.000 claims description 8
- 101000651439 Homo sapiens Prothrombin Proteins 0.000 claims description 7
- 102000003960 Ligases Human genes 0.000 claims description 7
- 108090000364 Ligases Proteins 0.000 claims description 7
- 230000003321 amplification Effects 0.000 claims description 7
- 239000000427 antigen Substances 0.000 claims description 7
- 102000036639 antigens Human genes 0.000 claims description 7
- 108091007433 antigens Proteins 0.000 claims description 7
- 238000002955 isolation Methods 0.000 claims description 7
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 7
- 230000002441 reversible effect Effects 0.000 claims description 7
- 238000010561 standard procedure Methods 0.000 claims description 7
- 102000003886 Glycoproteins Human genes 0.000 claims description 6
- 108090000288 Glycoproteins Proteins 0.000 claims description 6
- 239000001506 calcium phosphate Substances 0.000 claims description 6
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 6
- 235000011010 calcium phosphates Nutrition 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 239000012228 culture supernatant Substances 0.000 claims description 6
- 230000002068 genetic effect Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 241000894007 species Species 0.000 claims description 6
- 230000002103 transcriptional effect Effects 0.000 claims description 6
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 6
- 108091028026 C-DNA Proteins 0.000 claims description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 5
- 210000000805 cytoplasm Anatomy 0.000 claims description 5
- 108700004025 env Genes Proteins 0.000 claims description 5
- 101150030339 env gene Proteins 0.000 claims description 5
- 239000013604 expression vector Substances 0.000 claims description 5
- 238000010353 genetic engineering Methods 0.000 claims description 5
- 229960000027 human factor ix Drugs 0.000 claims description 5
- 229940039715 human prothrombin Drugs 0.000 claims description 5
- 239000003446 ligand Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 244000144977 poultry Species 0.000 claims description 5
- 239000002244 precipitate Substances 0.000 claims description 5
- 238000001890 transfection Methods 0.000 claims description 5
- 238000001262 western blot Methods 0.000 claims description 5
- 108020005065 3' Flanking Region Proteins 0.000 claims description 4
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims description 4
- 241000282552 Chlorocebus aethiops Species 0.000 claims description 4
- 101000577630 Homo sapiens Vitamin K-dependent protein S Proteins 0.000 claims description 4
- 108091029795 Intergenic region Proteins 0.000 claims description 4
- 239000000020 Nitrocellulose Substances 0.000 claims description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 4
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims description 4
- 238000013461 design Methods 0.000 claims description 4
- 230000006870 function Effects 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 230000000977 initiatory effect Effects 0.000 claims description 4
- 230000010354 integration Effects 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 229920001220 nitrocellulos Polymers 0.000 claims description 4
- 239000002243 precursor Substances 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 240000004731 Acer pseudoplatanus Species 0.000 claims description 3
- 235000002754 Acer pseudoplatanus Nutrition 0.000 claims description 3
- 108010041986 DNA Vaccines Proteins 0.000 claims description 3
- 229940021995 DNA vaccine Drugs 0.000 claims description 3
- 206010061598 Immunodeficiency Diseases 0.000 claims description 3
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 3
- 235000006679 Mentha X verticillata Nutrition 0.000 claims description 3
- 235000002899 Mentha suaveolens Nutrition 0.000 claims description 3
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims description 3
- 244000131360 Morinda citrifolia Species 0.000 claims description 3
- 101100460719 Mus musculus Noto gene Proteins 0.000 claims description 3
- 235000006485 Platanus occidentalis Nutrition 0.000 claims description 3
- 101150082969 SELP gene Proteins 0.000 claims description 3
- 101150036293 Selenop gene Proteins 0.000 claims description 3
- 108020004566 Transfer RNA Proteins 0.000 claims description 3
- 101100187345 Xenopus laevis noto gene Proteins 0.000 claims description 3
- 101150059062 apln gene Proteins 0.000 claims description 3
- 230000000712 assembly Effects 0.000 claims description 3
- 238000000429 assembly Methods 0.000 claims description 3
- 230000002238 attenuated effect Effects 0.000 claims description 3
- 235000013405 beer Nutrition 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 230000002950 deficient Effects 0.000 claims description 3
- 230000001419 dependent effect Effects 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 230000001605 fetal effect Effects 0.000 claims description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 3
- 230000007813 immunodeficiency Effects 0.000 claims description 3
- 239000013067 intermediate product Substances 0.000 claims description 3
- 108010087750 lysyl-plasminogen Proteins 0.000 claims description 3
- 238000002844 melting Methods 0.000 claims description 3
- 235000017524 noni Nutrition 0.000 claims description 3
- 239000000700 radioactive tracer Substances 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 238000010998 test method Methods 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 2
- 241000282693 Cercopithecidae Species 0.000 claims description 2
- 208000003322 Coinfection Diseases 0.000 claims description 2
- 101710139375 Corneodesmosin Proteins 0.000 claims description 2
- 102000012410 DNA Ligases Human genes 0.000 claims description 2
- 108010061982 DNA Ligases Proteins 0.000 claims description 2
- 230000003682 DNA packaging effect Effects 0.000 claims description 2
- 101710121417 Envelope glycoprotein Proteins 0.000 claims description 2
- 101000658547 Escherichia coli (strain K12) Type I restriction enzyme EcoKI endonuclease subunit Proteins 0.000 claims description 2
- 101000782195 Homo sapiens von Willebrand factor Proteins 0.000 claims description 2
- 108090000144 Human Proteins Proteins 0.000 claims description 2
- 102000003839 Human Proteins Human genes 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- 101100512354 Streptococcus pneumoniae (strain ATCC BAA-255 / R6) mapZ gene Proteins 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- -1 Thre nucleic acid Chemical class 0.000 claims description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 2
- 230000008859 change Effects 0.000 claims description 2
- 238000001962 electrophoresis Methods 0.000 claims description 2
- 238000012869 ethanol precipitation Methods 0.000 claims description 2
- 239000012894 fetal calf serum Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 230000002779 inactivation Effects 0.000 claims description 2
- 210000003292 kidney cell Anatomy 0.000 claims description 2
- 230000003505 mutagenic effect Effects 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 2
- 229920002401 polyacrylamide Polymers 0.000 claims description 2
- 230000002829 reductive effect Effects 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 230000001052 transient effect Effects 0.000 claims description 2
- 230000014621 translational initiation Effects 0.000 claims description 2
- 229960004854 viral vaccine Drugs 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 229940075420 xanthine Drugs 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims 143
- 108020004707 nucleic acids Proteins 0.000 claims 143
- 102100031780 Endonuclease Human genes 0.000 claims 18
- 239000002299 complementary DNA Substances 0.000 claims 17
- WOZDCBHUGJVJPL-AVGNSLFASA-N Arg-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N WOZDCBHUGJVJPL-AVGNSLFASA-N 0.000 claims 10
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 claims 7
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 6
- 229940088598 enzyme Drugs 0.000 claims 5
- 230000004927 fusion Effects 0.000 claims 5
- 108010050848 glycylleucine Proteins 0.000 claims 5
- 230000035772 mutation Effects 0.000 claims 5
- 108020004682 Single-Stranded DNA Proteins 0.000 claims 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims 4
- 229910052740 iodine Inorganic materials 0.000 claims 4
- 238000011160 research Methods 0.000 claims 4
- 230000028327 secretion Effects 0.000 claims 4
- PSUXEQYPYZLNER-QXEWZRGKSA-N Arg-Val-Asn Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O PSUXEQYPYZLNER-QXEWZRGKSA-N 0.000 claims 3
- 241000283707 Capra Species 0.000 claims 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 3
- DTICLBJHRYSJLH-GUBZILKMSA-N Met-Ala-Val Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O DTICLBJHRYSJLH-GUBZILKMSA-N 0.000 claims 3
- 229930003448 Vitamin K Natural products 0.000 claims 3
- 102000052932 human PROS1 Human genes 0.000 claims 3
- 229940099815 human protein s Drugs 0.000 claims 3
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 230000035899 viability Effects 0.000 claims 3
- 210000000605 viral structure Anatomy 0.000 claims 3
- 235000019168 vitamin K Nutrition 0.000 claims 3
- 239000011712 vitamin K Substances 0.000 claims 3
- 150000003721 vitamin K derivatives Chemical class 0.000 claims 3
- 229940046010 vitamin k Drugs 0.000 claims 3
- SNBCLPGEMZEWLU-QXFUBDJGSA-N 2-chloro-n-[[(2r,3s,5r)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl]acetamide Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CNC(=O)CCl)[C@@H](O)C1 SNBCLPGEMZEWLU-QXFUBDJGSA-N 0.000 claims 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims 2
- 102000004506 Blood Proteins Human genes 0.000 claims 2
- 108010017384 Blood Proteins Proteins 0.000 claims 2
- 241000282994 Cervidae Species 0.000 claims 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- 108091026898 Leader sequence (mRNA) Proteins 0.000 claims 2
- LESXFEZIFXFIQR-LURJTMIESA-N Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(O)=O LESXFEZIFXFIQR-LURJTMIESA-N 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- MDXAULHWGWETHF-SRVKXCTJSA-N Met-Arg-Val Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C(C)C)C(O)=O)CCCNC(N)=N MDXAULHWGWETHF-SRVKXCTJSA-N 0.000 claims 2
- KQBJYJXPZBNEIK-DCAQKATOSA-N Met-Glu-Arg Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCNC(N)=N KQBJYJXPZBNEIK-DCAQKATOSA-N 0.000 claims 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 2
- 101100173636 Rattus norvegicus Fhl2 gene Proteins 0.000 claims 2
- 206010042566 Superinfection Diseases 0.000 claims 2
- 150000007513 acids Chemical class 0.000 claims 2
- 235000003704 aspartic acid Nutrition 0.000 claims 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 239000003114 blood coagulation factor Substances 0.000 claims 2
- 229960000182 blood factors Drugs 0.000 claims 2
- 239000013599 cloning vector Substances 0.000 claims 2
- 230000021615 conjugation Effects 0.000 claims 2
- 238000010790 dilution Methods 0.000 claims 2
- 239000012895 dilution Substances 0.000 claims 2
- 210000003754 fetus Anatomy 0.000 claims 2
- 230000001976 improved effect Effects 0.000 claims 2
- 239000011630 iodine Substances 0.000 claims 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 claims 2
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims 2
- 229960000951 mycophenolic acid Drugs 0.000 claims 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 2
- 230000003389 potentiating effect Effects 0.000 claims 2
- 230000002000 scavenging effect Effects 0.000 claims 2
- 230000037432 silent mutation Effects 0.000 claims 2
- 229940104230 thymidine Drugs 0.000 claims 2
- 238000004448 titration Methods 0.000 claims 2
- 241001515965 unidentified phage Species 0.000 claims 2
- 108010073969 valyllysine Proteins 0.000 claims 2
- 108010047303 von Willebrand Factor Proteins 0.000 claims 2
- 102100036537 von Willebrand factor Human genes 0.000 claims 2
- 229960001134 von willebrand factor Drugs 0.000 claims 2
- OGNVQLDIPUXYDH-ZPKKHLQPSA-N (2R,3R,4S)-3-(2-methylpropanoylamino)-4-(4-phenyltriazol-1-yl)-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid Chemical compound CC(C)C(=O)N[C@H]1[C@H]([C@H](O)[C@H](O)CO)OC(C(O)=O)=C[C@@H]1N1N=NC(C=2C=CC=CC=2)=C1 OGNVQLDIPUXYDH-ZPKKHLQPSA-N 0.000 claims 1
- 108020005029 5' Flanking Region Proteins 0.000 claims 1
- LHEJDBBHZGISGW-UHFFFAOYSA-N 5-fluoro-3-(3-oxo-1h-2-benzofuran-1-yl)-1h-pyrimidine-2,4-dione Chemical compound O=C1C(F)=CNC(=O)N1C1C2=CC=CC=C2C(=O)O1 LHEJDBBHZGISGW-UHFFFAOYSA-N 0.000 claims 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- 229920000936 Agarose Polymers 0.000 claims 1
- XCIGOVDXZULBBV-DCAQKATOSA-N Ala-Val-Lys Chemical compound CC(C)[C@H](NC(=O)[C@H](C)N)C(=O)N[C@@H](CCCCN)C(O)=O XCIGOVDXZULBBV-DCAQKATOSA-N 0.000 claims 1
- 241000352333 Amegilla alpha Species 0.000 claims 1
- 108010039627 Aprotinin Proteins 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims 1
- 235000017491 Bambusa tulda Nutrition 0.000 claims 1
- 101100275473 Caenorhabditis elegans ctc-3 gene Proteins 0.000 claims 1
- 101100478890 Caenorhabditis elegans smo-1 gene Proteins 0.000 claims 1
- 101100311260 Caenorhabditis elegans sti-1 gene Proteins 0.000 claims 1
- 101100313377 Caenorhabditis elegans stip-1 gene Proteins 0.000 claims 1
- 241000282465 Canis Species 0.000 claims 1
- 108020004635 Complementary DNA Proteins 0.000 claims 1
- 102100031673 Corneodesmosin Human genes 0.000 claims 1
- 206010011469 Crying Diseases 0.000 claims 1
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 claims 1
- 101100364969 Dictyostelium discoideum scai gene Proteins 0.000 claims 1
- 101100313382 Dictyostelium discoideum stip-2 gene Proteins 0.000 claims 1
- 241001101242 Diuca Species 0.000 claims 1
- 206010013647 Drowning Diseases 0.000 claims 1
- 239000004243 E-number Substances 0.000 claims 1
- 235000019227 E-number Nutrition 0.000 claims 1
- 238000008157 ELISA kit Methods 0.000 claims 1
- 241000196324 Embryophyta Species 0.000 claims 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 claims 1
- 241001524679 Escherichia virus M13 Species 0.000 claims 1
- 102000009123 Fibrin Human genes 0.000 claims 1
- 108010073385 Fibrin Proteins 0.000 claims 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims 1
- 101150045567 GP16 gene Proteins 0.000 claims 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 claims 1
- DYFJZDDQPNIPAB-NHCYSSNCSA-N Glu-Arg-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O DYFJZDDQPNIPAB-NHCYSSNCSA-N 0.000 claims 1
- 241000058626 Gonora Species 0.000 claims 1
- 208000031220 Hemophilia Diseases 0.000 claims 1
- 208000009292 Hemophilia A Diseases 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 101500028775 Homo sapiens Glucagon Proteins 0.000 claims 1
- 101000856513 Homo sapiens Inactive N-acetyllactosaminide alpha-1,3-galactosyltransferase Proteins 0.000 claims 1
- 102100025509 Inactive N-acetyllactosaminide alpha-1,3-galactosyltransferase Human genes 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 241000725296 JDV virus Species 0.000 claims 1
- 101150062031 L gene Proteins 0.000 claims 1
- 244000147568 Laurus nobilis Species 0.000 claims 1
- 235000017858 Laurus nobilis Nutrition 0.000 claims 1
- 240000007472 Leucaena leucocephala Species 0.000 claims 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims 1
- 101000831624 Locusta migratoria Locustatachykinin-1 Proteins 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- 101001016849 Mus musculus Heat shock protein HSP 90-alpha Proteins 0.000 claims 1
- 101000985444 Mus musculus Heat shock protein HSP 90-beta Proteins 0.000 claims 1
- 101100364971 Mus musculus Scai gene Proteins 0.000 claims 1
- 101100365003 Mus musculus Scel gene Proteins 0.000 claims 1
- 101150008132 NDE1 gene Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 241000237502 Ostreidae Species 0.000 claims 1
- 101150072055 PAL1 gene Proteins 0.000 claims 1
- 241000168263 Palpatores Species 0.000 claims 1
- 241001494479 Pecora Species 0.000 claims 1
- 241001319148 Pharmacis Species 0.000 claims 1
- 244000082204 Phyllostachys viridis Species 0.000 claims 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 claims 1
- 206010035148 Plague Diseases 0.000 claims 1
- 101100516335 Rattus norvegicus Necab1 gene Proteins 0.000 claims 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 1
- 101150059016 TFIP11 gene Proteins 0.000 claims 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 claims 1
- 108091023045 Untranslated Region Proteins 0.000 claims 1
- JKHXYJKMNSSFFL-IUCAKERBSA-N Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN JKHXYJKMNSSFFL-IUCAKERBSA-N 0.000 claims 1
- 229920006103 Verton® Polymers 0.000 claims 1
- 108010067390 Viral Proteins Proteins 0.000 claims 1
- 101150095029 W gene Proteins 0.000 claims 1
- 241000607479 Yersinia pestis Species 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 229960004405 aprotinin Drugs 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 108010036533 arginylvaline Proteins 0.000 claims 1
- 101150047533 artP gene Proteins 0.000 claims 1
- 239000011425 bamboo Substances 0.000 claims 1
- 230000033228 biological regulation Effects 0.000 claims 1
- OIPMQULDKWSNGX-UHFFFAOYSA-N bis[[ethoxy(oxo)phosphaniumyl]oxy]alumanyloxy-ethoxy-oxophosphanium Chemical compound [Al+3].CCO[P+]([O-])=O.CCO[P+]([O-])=O.CCO[P+]([O-])=O OIPMQULDKWSNGX-UHFFFAOYSA-N 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 230000023555 blood coagulation Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 238000012512 characterization method Methods 0.000 claims 1
- 210000003837 chick embryo Anatomy 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 239000004927 clay Substances 0.000 claims 1
- 230000015271 coagulation Effects 0.000 claims 1
- 238000005345 coagulation Methods 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 239000000356 contaminant Substances 0.000 claims 1
- 229940028617 conventional vaccine Drugs 0.000 claims 1
- 230000001186 cumulative effect Effects 0.000 claims 1
- 230000008034 disappearance Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- 108010067298 endodeoxyribonuclease RsrII Proteins 0.000 claims 1
- 230000003511 endothelial effect Effects 0.000 claims 1
- 210000003038 endothelium Anatomy 0.000 claims 1
- 108010078428 env Gene Products Proteins 0.000 claims 1
- 238000010195 expression analysis Methods 0.000 claims 1
- 239000004744 fabric Substances 0.000 claims 1
- 230000002349 favourable effect Effects 0.000 claims 1
- 229950003499 fibrin Drugs 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 210000001061 forehead Anatomy 0.000 claims 1
- 238000012224 gene deletion Methods 0.000 claims 1
- 230000000762 glandular Effects 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 208000009429 hemophilia B Diseases 0.000 claims 1
- 229940034998 human von willebrand factor Drugs 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 238000011065 in-situ storage Methods 0.000 claims 1
- 230000000415 inactivating effect Effects 0.000 claims 1
- 238000010348 incorporation Methods 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims 1
- 150000002496 iodine Chemical class 0.000 claims 1
- 231100000518 lethal Toxicity 0.000 claims 1
- 230000001665 lethal effect Effects 0.000 claims 1
- 210000005229 liver cell Anatomy 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 231100000219 mutagenic Toxicity 0.000 claims 1
- 101150115538 nero gene Proteins 0.000 claims 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 claims 1
- 108091027963 non-coding RNA Proteins 0.000 claims 1
- 102000042567 non-coding RNA Human genes 0.000 claims 1
- 235000020636 oyster Nutrition 0.000 claims 1
- 239000005022 packaging material Substances 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 239000008188 pellet Substances 0.000 claims 1
- 230000007505 plaque formation Effects 0.000 claims 1
- 229940012957 plasmin Drugs 0.000 claims 1
- 239000011148 porous material Substances 0.000 claims 1
- 230000004481 post-translational protein modification Effects 0.000 claims 1
- 230000001323 posttranslational effect Effects 0.000 claims 1
- ZMRUPTIKESYGQW-UHFFFAOYSA-N propranolol hydrochloride Chemical compound [H+].[Cl-].C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 ZMRUPTIKESYGQW-UHFFFAOYSA-N 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 230000020978 protein processing Effects 0.000 claims 1
- 238000002271 resection Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000006152 selective media Substances 0.000 claims 1
- 230000035807 sensation Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 238000009987 spinning Methods 0.000 claims 1
- 230000002269 spontaneous effect Effects 0.000 claims 1
- 238000010186 staining Methods 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 210000004243 sweat Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- MBYLVOKEDDQJDY-UHFFFAOYSA-N tris(2-aminoethyl)amine Chemical compound NCCN(CCN)CCN MBYLVOKEDDQJDY-UHFFFAOYSA-N 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
- 230000017613 viral reproduction Effects 0.000 claims 1
- 239000000277 virosome Substances 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 231100000614 poison Toxicity 0.000 description 9
- 230000003834 intracellular effect Effects 0.000 description 7
- 239000002574 poison Substances 0.000 description 7
- 241000450599 DNA viruses Species 0.000 description 6
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241000701372 Iridovirus Species 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 238000001712 DNA sequencing Methods 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 235000021251 pulses Nutrition 0.000 description 3
- 230000003362 replicative effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 229960003087 tioguanine Drugs 0.000 description 3
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
- 101150056788 A51R gene Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108020003215 DNA Probes Proteins 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 208000000666 Fowlpox Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 101900209501 Vaccinia virus Thymidine kinase Proteins 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 230000030609 dephosphorylation Effects 0.000 description 2
- 238000006209 dephosphorylation reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- 229910052753 mercury Inorganic materials 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 230000023790 viral DNA cleavage Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- KWKAKUADMBZCLK-UHFFFAOYSA-N 1-octene Chemical compound CCCCCCC=C KWKAKUADMBZCLK-UHFFFAOYSA-N 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- 101150101112 7 gene Proteins 0.000 description 1
- 101150053695 A45R gene Proteins 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 241000700663 Avipoxvirus Species 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 241000616862 Belliella Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241001609030 Brosme brosme Species 0.000 description 1
- 101100148606 Caenorhabditis elegans pst-1 gene Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 101100398448 Cowpox virus (strain GRI-90 / Grishak) TMK gene Proteins 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 1
- 241000701867 Enterobacteria phage T7 Species 0.000 description 1
- 235000014066 European mistletoe Nutrition 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 1
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000700629 Orthopoxvirus Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 241000932156 Proteinus Species 0.000 description 1
- 244000152640 Rhipsalis cassutha Species 0.000 description 1
- 235000012300 Rhipsalis cassutha Nutrition 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 235000019892 Stellar Nutrition 0.000 description 1
- 101100321855 Vaccinia virus (strain Ankara) MVA164R gene Proteins 0.000 description 1
- 101100321857 Vaccinia virus (strain Western Reserve) VACWR177 gene Proteins 0.000 description 1
- KRNYOVHEKOBTEF-YUMQZZPRSA-N Val-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(O)=O KRNYOVHEKOBTEF-YUMQZZPRSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 241000902900 cellular organisms Species 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000003500 gene array Methods 0.000 description 1
- 238000012248 genetic selection Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 208000009091 myxoma Diseases 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000009471 passive packaging Methods 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 108010021889 valylvaline Proteins 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6429—Thrombin (3.4.21.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21005—Thrombin (3.4.21.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/750,080 US5445953A (en) | 1991-08-26 | 1991-08-26 | Direct molecular cloning of a modified poxvirus genome |
| US91473892A | 1992-07-20 | 1992-07-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK264192A3 true SK264192A3 (en) | 1995-08-09 |
Family
ID=27115227
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK2641-92A SK264192A3 (en) | 1991-08-26 | 1992-08-26 | Direct molecular cloning of modificated gen of eucaryotic cytoplasmic dna-virus |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US6265183B1 (cs) |
| EP (1) | EP0561034B1 (cs) |
| JP (1) | JPH06261763A (cs) |
| AT (1) | ATE181108T1 (cs) |
| AU (1) | AU652467B2 (cs) |
| BR (1) | BR9203322A (cs) |
| CA (1) | CA2076839C (cs) |
| CZ (1) | CZ264192A3 (cs) |
| DE (1) | DE69229390T2 (cs) |
| FI (1) | FI111384B (cs) |
| HU (1) | HU219369B (cs) |
| MX (1) | MX9204926A (cs) |
| NO (1) | NO310306B1 (cs) |
| PL (1) | PL295733A1 (cs) |
| SI (1) | SI9200190A (cs) |
| SK (1) | SK264192A3 (cs) |
| YU (1) | YU79092A (cs) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8927722D0 (en) * | 1989-12-07 | 1990-02-07 | British Bio Technology | Proteins and nucleic acids |
| EP0753581A1 (en) | 1995-07-10 | 1997-01-15 | Immuno Ag | Improved recombinant eukaryotic cytoplasmic viruses, method for their production and their use as vaccines |
| US20030138454A1 (en) * | 1997-06-09 | 2003-07-24 | Oxxon Pharmaccines, Ltd. | Vaccination method |
| GB9711957D0 (en) * | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
| WO2000073479A1 (en) * | 1999-05-28 | 2000-12-07 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector |
| US20040063653A1 (en) * | 2000-12-21 | 2004-04-01 | Shiver John W. | Polynucleotide vaccines expressing codon optimized hiv-1 pol and modified hiv-1 pol |
| CA2401974C (en) | 2000-03-02 | 2013-07-02 | Emory University | Dna expression vectors and methods of use |
| US20040105871A1 (en) * | 2000-03-02 | 2004-06-03 | Robinson Harriet L. | Compositions and methods for generating an immune response |
| US8623379B2 (en) * | 2000-03-02 | 2014-01-07 | Emory University | Compositions and methods for generating an immune response |
| DE60234018D1 (de) * | 2001-03-08 | 2009-11-26 | Univ Emory | Mva-exprimierende modifizierte hiv-envelope-, gag-, und pol-gene |
| US7223740B2 (en) | 2001-05-23 | 2007-05-29 | Fornix Biosciences N.V. | Vectors for enhanced expression of VEGF for atrial disease treatment |
| AU2002309335A1 (en) * | 2001-05-23 | 2002-12-03 | Fornix Biosciences N.V. | Vectors for enhanced expression of vegf for disease treatment |
| GB0118532D0 (en) * | 2001-07-30 | 2001-09-19 | Isis Innovation | Materials and methods relating to improved vaccination strategies |
| GB2382578A (en) * | 2001-11-30 | 2003-06-04 | Isis Innovation | Fowlpox-based vaccine |
| CN1596126A (zh) * | 2001-11-30 | 2005-03-16 | 埃西斯创新有限公司 | 疫苗 |
| CA2425021A1 (en) * | 2002-04-12 | 2003-10-12 | Sumitomo Electric Industries, Ltd. | Control of the ratio of lap to lip |
| CN101831411A (zh) * | 2002-05-16 | 2010-09-15 | 巴法里安诺迪克有限公司 | 表达插入痘病毒基因组中的同源基因的重组痘病毒 |
| GB0215621D0 (en) * | 2002-07-05 | 2002-08-14 | Imp College Innovations Ltd | Improved poxvirus vaccines |
| US20050175627A1 (en) * | 2003-09-24 | 2005-08-11 | Oxxon Therapeutics Ltd. | HIV pharmaccines |
| US20090098529A1 (en) * | 2006-10-16 | 2009-04-16 | Nanhai Chen | Methods for attenuating virus strains for diagnostic and therapeutic uses |
| US8202967B2 (en) | 2006-10-27 | 2012-06-19 | Boehringer Ingelheim Vetmedica, Inc. | H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use |
| GB201006405D0 (en) | 2010-04-16 | 2010-06-02 | Isis Innovation | Poxvirus expression system |
| AR083533A1 (es) | 2010-10-22 | 2013-03-06 | Boehringer Ingelheim Vetmed | Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe |
| CN114262690A (zh) | 2011-04-15 | 2022-04-01 | 吉恩勒克斯公司 | 减毒的痘苗病毒的克隆毒株及其使用方法 |
| AR088028A1 (es) | 2011-08-15 | 2014-05-07 | Boehringer Ingelheim Vetmed | Proteinas h5, de h5n1 para un uso medicinal |
| US20140140959A1 (en) | 2012-10-05 | 2014-05-22 | Aladar A. Szalay | Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes |
| MX360137B (es) | 2013-02-21 | 2018-10-24 | Boehringer Ingelheim Vetmedica Gmbh | Proteínas h5 del virus de la influenza h5n1 para usarse como un medicamento. |
| WO2015103438A2 (en) | 2014-01-02 | 2015-07-09 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
| BR102015012334A2 (pt) * | 2015-05-27 | 2016-11-29 | Fundação Hemoct De Ribeirão Preto Fundherp | processo de produção do fator vii de coagulação sanguínea e fator vii de coagulação sanguínea |
| AU2017206102C1 (en) | 2016-01-08 | 2022-02-10 | Geovax Inc. | Compositions and methods for generating an immune response to a tumor associated antigen |
| US11311612B2 (en) | 2017-09-19 | 2022-04-26 | Geovax, Inc. | Compositions and methods for generating an immune response to treat or prevent malaria |
| WO2024011250A1 (en) | 2022-07-08 | 2024-01-11 | Viromissile, Inc. | Oncolytic vaccinia viruses and recombinant viruses and methods of use thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
| US5110587A (en) | 1981-12-24 | 1992-05-05 | Health Research, Incorporated | Immunogenic composition comprising synthetically modified vaccinia virus |
| US5505941A (en) | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
| US5155020A (en) | 1989-03-08 | 1992-10-13 | Health Research Inc. | Recombinant poxvirus host range selection system |
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US5364773A (en) | 1991-03-07 | 1994-11-15 | Virogenetics Corporation | Genetically engineered vaccine strain |
| US5338683A (en) | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
| US5135855A (en) * | 1986-09-03 | 1992-08-04 | The United States Of America As Represented By The Department Of Health And Human Services | Rapid, versatile and simple system for expressing genes in eukaryotic cells |
| US5266313A (en) | 1987-02-03 | 1993-11-30 | The United States Of America As Represented By The Department Of Health And Human Services | Raccoon poxvirus as a gene expression and vaccine vector for genes of rabies virus and other organisms |
| FR2619314B1 (fr) * | 1987-08-11 | 1990-06-15 | Transgene Sa | Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant |
| AU625584B2 (en) | 1989-03-08 | 1992-07-16 | Health Research Inc. | Recombinant poxvirus host selection system |
| US5225336A (en) | 1989-03-08 | 1993-07-06 | Health Research Incorporated | Recombinant poxvirus host range selection system |
| HUT63459A (en) * | 1990-01-26 | 1993-08-30 | Immuno Ag | Blood factors produced by recommbinant process, process for expressing them, as well as recombinant vaccine viruses used in the process |
| US5204243A (en) | 1990-02-14 | 1993-04-20 | Health Research Incorporated | Recombinant poxvirus internal cores |
| DE69132311T2 (de) | 1990-09-25 | 2000-12-14 | Cantab Pharmaceuticals Research Ltd., Cambridge | Bei einer transkomplementenden zellinie erzeugter defektiver virenimpfstoff |
| US5863542A (en) | 1991-03-07 | 1999-01-26 | Virogenetics Corporation | Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts |
| US5997878A (en) | 1991-03-07 | 1999-12-07 | Connaught Laboratories | Recombinant poxvirus-cytomegalovirus, compositions and uses |
| JP3602530B2 (ja) | 1991-03-07 | 2004-12-15 | ヴァイロジェネティクス コーポレイション | 遺伝子操作したワクチン菌株 |
| US5989561A (en) | 1991-03-07 | 1999-11-23 | Virogenetics Corporation | Recombinant poxvirus-calicivirus rabbit hemorrhagic disease virus (RHDV) compositions and uses |
| US5843456A (en) | 1991-03-07 | 1998-12-01 | Virogenetics Corporation | Alvac poxvirus-rabies compositions and combination compositions and uses |
| US5626850A (en) | 1992-07-30 | 1997-05-06 | Akzo Nobel N.V. | Non-shedding live herpesvirus vaccine |
| EP1840209A3 (en) | 1995-01-13 | 2008-03-05 | Virogenetics Corporation | Adeno-associated virus vectors and use thereof |
-
1992
- 1992-08-11 AT AT92113675T patent/ATE181108T1/de not_active IP Right Cessation
- 1992-08-11 DE DE69229390T patent/DE69229390T2/de not_active Expired - Lifetime
- 1992-08-11 EP EP92113675A patent/EP0561034B1/en not_active Expired - Lifetime
- 1992-08-25 AU AU21269/92A patent/AU652467B2/en not_active Ceased
- 1992-08-25 HU HU9202737A patent/HU219369B/hu not_active IP Right Cessation
- 1992-08-25 CA CA002076839A patent/CA2076839C/en not_active Expired - Fee Related
- 1992-08-25 NO NO19923323A patent/NO310306B1/no not_active IP Right Cessation
- 1992-08-25 YU YU79092A patent/YU79092A/sh unknown
- 1992-08-26 SK SK2641-92A patent/SK264192A3/sk unknown
- 1992-08-26 CZ CS922641A patent/CZ264192A3/cs unknown
- 1992-08-26 MX MX9204926A patent/MX9204926A/es unknown
- 1992-08-26 PL PL29573392A patent/PL295733A1/xx unknown
- 1992-08-26 FI FI923828A patent/FI111384B/fi active
- 1992-08-26 BR BR929203322A patent/BR9203322A/pt not_active Application Discontinuation
- 1992-08-26 SI SI19929200190A patent/SI9200190A/sl unknown
- 1992-08-26 JP JP4250826A patent/JPH06261763A/ja active Pending
-
1994
- 1994-12-19 US US08/358,928 patent/US6265183B1/en not_active Expired - Fee Related
-
1996
- 1996-05-22 US US08/651,472 patent/US6103244A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| MX9204926A (es) | 1994-02-28 |
| NO923323L (no) | 1993-03-01 |
| EP0561034A3 (cs) | 1995-04-26 |
| CA2076839A1 (en) | 1993-02-27 |
| NO310306B1 (no) | 2001-06-18 |
| HU219369B (en) | 2001-03-28 |
| BR9203322A (pt) | 1993-03-30 |
| CZ264192A3 (en) | 1993-08-11 |
| US6265183B1 (en) | 2001-07-24 |
| EP0561034A2 (en) | 1993-09-22 |
| DE69229390D1 (de) | 1999-07-15 |
| EP0561034B1 (en) | 1999-06-09 |
| YU79092A (sh) | 1995-12-04 |
| AU652467B2 (en) | 1994-08-25 |
| ATE181108T1 (de) | 1999-06-15 |
| FI923828A0 (fi) | 1992-08-26 |
| CA2076839C (en) | 2007-06-12 |
| HUT69927A (en) | 1995-09-28 |
| NO923323D0 (no) | 1992-08-25 |
| AU2126992A (en) | 1993-03-04 |
| PL295733A1 (en) | 1993-05-17 |
| FI111384B (fi) | 2003-07-15 |
| DE69229390T2 (de) | 1999-11-11 |
| US6103244A (en) | 2000-08-15 |
| JPH06261763A (ja) | 1994-09-20 |
| SI9200190A (en) | 1993-03-31 |
| FI923828A (fi) | 1993-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI111384B (fi) | Menetelmä modifioidun selkärankaispoxviruksen molekylaariseksi kloonaamiseksi, modifioitu virus, sen DNA ja sen käyttö | |
| CN111344395B (zh) | 产生经修饰的自然杀伤细胞的方法及使用方法 | |
| KR102604096B1 (ko) | 윌슨병을 치료하기 위한 유전자 치료 | |
| KR102550926B1 (ko) | 이중 항체 구축물을 발현하는 aav를 포함하는 조성물 및 이들의 용도 | |
| CA2447450C (en) | Corona-virus-like particles comprising functionally deleted genomes | |
| KR20180097631A (ko) | 핵산을 와우 및 전정 세포에 전달하기 위한 물질 및 방법 | |
| KR20160138298A (ko) | 세포 면역요법을 위한 방법 및 조성물 | |
| KR20170108946A (ko) | Fc 수용체-유사 5를 표적화하는 키메라 항원 수용체 및 그의 용도 | |
| JP2023036921A (ja) | 蝸牛および前庭細胞に核酸を送達するための物質および方法 | |
| AU2018235957B2 (en) | Engraftable cell-based immunotherapy for long-term delivery of therapeutic proteins | |
| CN111733174B (zh) | 一种分离的核酸分子及其用途 | |
| CN112912112A (zh) | 肝特异性核酸调节元件以及其方法及用途 | |
| CN114990157B (zh) | 用于构建lmna基因突变的扩张型心肌病模型猪核移植供体细胞的基因编辑系统及其应用 | |
| CN113164560A (zh) | 改善基因疗法的新工具及其用途 | |
| CN107849583A (zh) | 使用细胞分裂基因座控制细胞增殖的工具和方法 | |
| KR102679920B1 (ko) | 모노머형 스트렙타비딘을 발현하는 균주 및 비오틴화된 화합물을 포함하는 암 세포 표적용 조성물 | |
| CN114958762B (zh) | 一种构建神经组织特异过表达人源snca的帕金森病模型猪的方法及应用 | |
| KR20220142502A (ko) | 근육 특이적 핵산 조절 요소 및 이의 방법 및 용도 | |
| CN114958758B (zh) | 一种乳腺癌模型猪的构建方法及应用 | |
| KR102712198B1 (ko) | 재조합 발생이 최소화된 유전자치료 벡터, 상기 벡터를 포함하는 재조합 레트로바이러스 및 상기 재조합 레트로바이러스를 포함하는 암의 예방 또는 치료용 약학 조성물 | |
| CN116323924B (zh) | 基因疗法载体、包含载体的重组逆转录病毒和用于预防或治疗癌症的药物组合物 | |
| CA2515166C (en) | Direct molecular cloning of a modified eukaryotic cytoplasmic dna virus genome | |
| CA2558864C (en) | Direct molecular cloning of a modified eukaryotic cytoplasmic dna virus genome | |
| JPH01148183A (ja) | 組み換えワクチニアウイルス |